Figure 6.1
Adjusted all-cause mortality (deaths per 1,000 patient-years) by treatment modality (a) overall, dialysis, and transplant, and (b) hemodialysis and peritoneal dialysis, for period-prevalent patients, 1996-2013
(a) Overall, dialysis, and transplant
Overall, dialysis, and transplant
(b) Hemodialysis and peritoneal dialysis
Hemodialysis and peritoneal dialysis
Data Source: Reference Tables H.2_adj, H4_adj, H.8_adj, H.9_adj, and H.10_adj; and special analyses, USRDS ESRD Database. Adjusted for age, sex, race, ethnicity, primary diagnosis and vintage. Reference population: period prevalent ESRD patients, 2011. Abbreviations: HD, hemodialysis; PD, peritoneal dialysis.

Figure 6.2
Adjusted all-cause mortality (deaths per 1,000 patient-years) by treatment modality, cohort (year of ESRD onset), and number of years after start of dialysis among incident (a) hemodialysis patients and (b) peritoneal dialysis patients, 1996, 2001, 2006, and 2011
(a) Hemodialysis patients
Hemodialysis patients
(b) Peritoneal dialysis patients
Peritoneal dialysis patients
Data Source: Special analyses, USRDS ESRD Database. Adjusted for age, sex, race, and primary diagnosis. Reference population: period prevalent ESRD patients, 2011. Abbreviation: ESRD, end-stage renal disease.

Figure 6.3
vol 2 Figure 6.3 Adjusted mortality (deaths per 1000 patient-years) by treatment modality and number of months after treatment initiation among ESRD patients (a) under age 65 and (b) aged 65 and over, 2013
(a) Under age 65
Under age 65
(b) Aged 65 and over
Aged 65 and over
Data Source: Special analyses, USRDS ESRD Database. Adjusted (age, race, sex, ethnicity, and primary diagnosis) mortality among 2013 incident ESRD patients during the first year of therapy. Reference population: incident ESRD patients, 2011. Abbreviations: ESRD, end-stage renal disease; HD, hemodialysis; PD, peritoneal.

Adjusted all-cause mortality (deaths per 1,000 patient-years) (a) by age and race, and (b) by age and sex, among ESRD patients, 2014

Unadjusted percentages of deaths due to cardiovascular disease (CVD), infection, other specified causes, and with missing data, by modality among ESRD patients, 2013

Adjusted survival (%) by treatment modality and incident cohort year (year of ESRD onset)

Expected remaining lifetime (years) by age, sex, and treatment modality of prevalent dialysis patients, prevalent transplant patients, and the general U.S. population (2013), based on USRDS data and the National Vital Statistics Report (2013)

Adjusted mortality (deaths per 1,000 patient-years) by age, sex, treatment modality, and comorbidity among ESRD patients and the general Medicare population, 2013-2014

Figure 6.4
Adjusted mortality (deaths per 1,000 patient-years) by calendar year, treatment modality, and comorbidity among ESRD patients and comorbidity-specific Medicare populations aged 65 & older, 1996-2014
Adjusted mortality (deaths per 1,000 patient-years) by calendar year, treatment modality, and comorbidity among ESRD patients and comorbidity-specific Medicare populations aged 65 & older, 1996-2014
Data Source: Special analyses, USRDS ESRD Database and Medicare 5% sample. Unadjusted and adjusted (sex and race) mortality rates starting with the January 1 point prevalent sample in the ESRD and general populations, aged 65 and older (per 1,000 patient-years at risk). Reference population: period prevalent ESRD patients, 2012. Abbreviations: AMI, acute myocardial infarction; CHF, congestive heart failure; CVA/TIA, cerebrovascular accident/transient ischemic attack; ESRD, end-stage renal disease.